Megestrol Acetate Tablets

Offering you a complete choice of products which include megestrol acetate tablets.

Megestrol Acetate Tablets

Request Callback

₹ 900 / Strip Get Latest Price

Product Brochure
Strength160 mg
BrandYour Brand
Pack Size10*10 Tablet
Tablets per Pack10 Tablets
FormTablet
UsageCancer Care
Brand NameYour Brand Name
ManufacturerTrireme Lifesciences Pvt. Ltd.
Country of OriginMade in India
Pack TypeStrip
Pack TypeBox

Minimum order quantity: 10000 Strip

Trireme Lifesciences Pvt. Ltd. presents "Megestrol Acetate Tablets" in third party.

Megestrol Acetate Tablets are synthetic progestins widely used for the treatment of loss of appetite and significant weight loss (cachexia) in patients with HIV/AIDS or cancer. It also plays a supportive role in the treatment of breast and endometrial cancers due to its anti-estrogenic activity.

Ideal for oncology, palliative care, and HIV care programs, this product offers therapeutic value in severe appetite loss and hormone-responsive tumors.

�� Therapeutic Uses

✔️ Cancer Cachexia & Weight Loss
✔️ Advanced Breast & Endometrial Cancer
✔️ Appetite Stimulant in HIV/AIDS Patients
✔️ Hormone Therapy Support in Palliative Care

�� Key Features

✅ WHO-GMP Certified Manufacturing
✅ DCGI Approved Composition
✅ High Stability & Shelf Life
✅ Low Minimum Order Quantity (MOQ)
✅ Custom Packaging with Brand Name

�� Why Choose Us?

�� End-to-End Third Party Manufacturing Support
�� Lab-Tested Raw Material | Stringent Quality Control
�� Customizable Brand Name, Design & Box Style
�� Fast Delivery Across India
�� Competitive Pricing & Transparent Process
Product Name: Your Brand Name
Composition Options:
Megestrol Acetate 160 mg
Megestrol Acetate 40 mg
Form: Tablets
Packaging: 10x10 / 10x1x10 Blister / Alu-Alu
Shelf Life: 24 months
Available As: Third Party / PCD / Own Brand

X

Contact Us

M Z Alam (CEO & Director)
Trireme Life Sciences Private Limited
1st Floor, 194/1 , A1, Picnic Garden Road
Tiljala, Kolkata - 700039, West Bengal, India

Get Directions
Send Email
Share: